Tus-Pharmaceutical Group Co., Ltd.

000590

CNE000000701

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 15/05/2024 am IST			5-day change	1st Jan Change
6.64 ^CNY	-0.90%		-3.91%	-25.89%

25/04	Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
27/03	Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tus-Pharmaceutical Group Co., Ltd. agreed to acquire 100% stake in Guangdong Sinotau Pharmaceutical Co., Ltd. from Beijing Xiantongyuan Pharmaceutical Technology Co., Ltd. and Li Yinqiang fron CNY220 million.

August 03, 2022

Tus-Pharmaceutical Group Co., Ltd. (SZSE:000590) agreed to acquire 100% stake in Guangdong Sinotau Pharmaceutical Co., Ltd. from Beijing Xiantongyuan Pharmaceutical Technology Co., Ltd. and Li Yinqiang for CNY 220 million on August 2, 2022. Tus-Pharmaceutical Group Co., Ltd. (SZSE:000590) signed the equity transfer agreement to acquire Guangdong Sinotau Pharmaceutical Co., Ltd. from Beijing Xiantongyuan Pharmaceutical Technology Co., Ltd. and Li Yinqiang on August 22, 2022. In Guangdong Sinotau Pharmaceutical Co., Ltd. Beijing Xiantongyuan Pharmaceutical Technology Co., Ltd. holds 90% and Li Yinqiang holds 10% shares.

For the year ended March 31, 2022 Guangdong Sinotau Pharmaceutical Co., Ltd. reported Total assets of CNY 98.28 million and OwnerÃ†s equity of CNY 36 million. The transaction is approved by the Tus-Pharmaceutical Group Co., Ltd. (SZSE:000590) 9th directorate and the target companyÃ†s shareholdersÃ† meeting already approved this transaction.

Latest news about Tus-Pharmaceutical Group Co., Ltd.

Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
Tus Pharmaceutical to Boost Investment in Chemical Park Project	12/01	MT
Tus-Pharmaceutical Group Co., Ltd. agreed to acquire 55% stake in Wuhan Medtek Pharmaceutical Co., Ltd. from Tan Yunliang and Wang Zhong for approximately CNY 140 million.	12/01	CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/23/27	CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	22/23/22	CI
Tus-Pharmaceutical Group Co., Ltd. Approves Board Appointments	20/23/20	CI
Tus Pharmaceutical to Set Up New Marketing Subsidiary	19/23/19	MT
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/23/25	CI
Guhan Traditional Chinese Medicine Co., Ltd. announced that it expects to receive CNY 22 million in funding from Tus-Pharmaceutical Group Co., Ltd.	30/22/30	CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/22/27	CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	29/22/29	CI
Tus-Pharmaceutical Group Co., Ltd. completed the acquisition of Guangdong Sinotau Pharmaceutical Co., Ltd. from Beijing Xiantongyuan Pharmaceutical Technology Co., Ltd. and Li Yinqiang.	24/22/24	CI
Tus Pharmaceutical to Buy Local Drugmaker Xiantong for $33 Million	03/22/03	MT
Tus-Pharmaceutical Group Co., Ltd. agreed to acquire 100% stake in Guangdong Sinotau Pharmaceutical Co., Ltd. from Beijing Xiantongyuan Pharmaceutical Technology Co., Ltd. and Li Yinqiang fron CNY220 million.	03/22/03	CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	28/22/28	CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	30/22/30	CI
Hunan Tus-Pharmaceutical Biological Co., Ltd. announced that it expects to receive CNY 25 million in funding from Tus-Pharmaceutical Group Co., Ltd., Ningbo Yiduoduo Electronic Commerce Co., Ltd.	18/22/18	CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	27/21/27	CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	27/21/27	CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	29/21/29	CI
Tus-Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	29/21/29	CI
Tus Pharmaceutical : Adopts New Name	23/20/23	MT
Tus-Guhan Group Corp.,Ltd. Approves Board Elections	12/20/12	CI
Tus-Guhan Group Corp.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	29/20/29	CI

Chart Tus-Pharmaceutical Group Co., Ltd.

Duration

Period

Chart Tus-Pharmaceutical Group Co., Ltd.

More charts

Company Profile

Tus Pharmaceutical Group Co Ltd, formerly Tus-Guhan Group Corp Ltd, is principally engaged in the manufacture and sale of pharmaceuticals. The Company provides Chinese medicines, including Chinese healthcare products, medicines for cold treatment and anti hyperlipemia medicines, among others. It also provides western medicine preparations, including clindamycin phosphate for injection, lomefloxacin hydrochloride for injection and levofloxacin lactate for injection, among others. The Company distributes its products in domestic markets.

Sector

Pharmaceuticals

Calendar

29/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TUS-PHARMACEUTICAL GROUP CO., LTD.	-25.89%	220M
ELI LILLY AND COMPANY	+35.01%	709B
NOVO NORDISK A/S	+31.16%	595B
JOHNSON & JOHNSON	-2.60%	367B
MERCK & CO., INC.	+20.83%	334B
ABBVIE INC.	+5.69%	289B
ASTRAZENECA PLC	+14.68%	239B
NOVARTIS AG	+9.40%	211B
ROCHE HOLDING AG	-4.13%	203B
AMGEN INC.	+10.77%	171B

Other Pharmaceuticals